Depletion of teratoma-forming pluripotent stem cells
Compositions and methods are provided for depletion of pluripotent cells. In one embodiment of the invention, methods are provided for depletion of pluripotent cells from a mixed population of differentiated cells and stem cells, to provide a population of cells substantially free of pluripotent stem cells. Monoclonal antibodies useful in depletion and in identification of pluripotent stem cells are also provided.
1. A method of depleting teratoma-forming pluripotent stem cells from a mixed cell population comprising cells differentiated from the pluripotent stem cells, the method comprising:
contacting a mixed population of cells suspected of comprising pluripotent stem cells with an antibody that specifically binds an H type-1 antigen epitope recognized by monoclonal antibody 8e11; and
depleting from said population those cells that bind to the antibody, to provide a differentiated cell population depleted of teratoma-forming pluripotent stem cells.
2. The method of claim 1 , wherein the antibody that specifically binds an H type-1 antigen is monoclonal antibody 8e11.
3. The method of claim 1 , further comprising contacting the mixed population of cells suspected of comprising pluripotent stem cells with a cocktail of antibodies specific for CD9, CD30, CD50, CD90, CD200 and H type-1 antigen; and
depleting from said population those cells that bind to the cocktail of antibodies.
4. The method of claim 1 , wherein the contacting is performed in vitro.
5. The method of claim 3 , wherein the pluripotent stem cell is one or more of an induced pluripotent stem cell (iPS), embryonic stem cell and embryonic germ cell.
6. The method of claim 1 wherein the depleted population contains less than 1 in 10 9 teratogenic pluripotent cells.
7. The method of claim 1 wherein said contacting is performed in vivo.
8. The method of claim 7 , wherein the pluripotent stem cell is present.